Sanofi Pasteur, A Sanofi Company

This study is testing a new vaccine that aims to protect against five types of meningococcal bacteria (A, B, C, W, Y) that can cause serious infections like meningitis. The trial includes healthy children aged 2 to 9 years, toddlers 12 to 15 months, and infants 2 months old. Rese…

This study tests a new vaccine (PCV21) in healthy infants to see if it safely helps their bodies build defenses against pneumococcal bacteria, which can cause serious illnesses like pneumonia and meningitis. About 1,700 babies will receive either the new vaccine or an existing on…

This study tests a new mRNA vaccine designed to protect adults aged 60 and older from two respiratory viruses: human metapneumovirus (hMPV) and respiratory syncytial virus (RSV). The vaccine uses lipid nanoparticles to deliver the mRNA. Around 1,530 participants will receive eith…

This study tests a new 21-valent pneumococcal vaccine (PCV21) in healthy infants, toddlers, children, and adolescents who need catch-up vaccination. The goal is to see if PCV21 is safe and triggers a strong immune response compared to an existing 20-valent vaccine. About 1,268 pa…

This study follows about 100 healthy adults aged 18 to 29 who have had Epstein-Barr virus (EBV) in the past. Researchers collect blood and saliva samples over 6 to 12 months to see when the virus becomes active again and how the immune system responds. No treatment or vaccine is …